Tandem Diabetes Care reported $64.11M in Cash and Equivalent for its fiscal quarter ending in June of 2025.



Financials
Assets USD 875.74M
Cost of Sales USD 114.82M
Current Assets USD 614.82M
Debt USD 449.01M
EBIT USD -31.86M
EBITDA USD -1.85M
Employees 2.65K
Interest Income USD 4.19M
Loan Capital USD 309.15M
Net Income USD -52.4M
Operating Expenses USD 272.54M
Operating Profit USD -31.86M
Pre-Tax Profit USD -57.72M
Sales Revenues USD 240.68M
Stock USD 142.57M
Trade Creditors USD 55.84M
Trade Debtors USD 128.44M

Cash And Equivalent Change Date
Abbott USD 6.95B 419M Jun/2025
Align Technology USD 873.01M 170.88M Mar/2025
AtriCure USD 117.8M 17.91M Jun/2025
Baxter International USD 2.29B 530M Mar/2025
Becton, Dickinson and Co. USD 735M 68M Jun/2025
Boston Scientific USD 725M 311M Mar/2025
Cooper Companies USD 124.9M 8.7M Jul/2025
Dexcom USD 1.16B 254.1M Jun/2025
Edwards Lifesciences USD 3.14B 95.4M Mar/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Globus Medical USD 229.45M 231.82M Jun/2025
ICU Medical USD 300.02M 10.32M Jun/2025
Insulet USD 1.12B 107M Jun/2025
Integra LifeSciences USD 217.91M 21.19M Jun/2025
Intuitive Surgical USD 9.53B 431.3M Jun/2025
J&J USD 38.47B 32.35B Mar/2025
Masimo USD 149.6M 18.8M Jun/2025
Medtronic USD 2.22B 978M Apr/2025
Merit Medical Systems USD 341.82M 53.71M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Stryker USD 2.38B 55M Jun/2025
Tandem Diabetes Care USD 64.11M 10.54M Jun/2025
Teleflex USD 253.7M 30.42M Jun/2025
Zimmer Biomet Holdings USD 556.9M 827.6M Jun/2025